228 related articles for article (PubMed ID: 33988300)
21. Elevated expression of interleukin-27, IL-35, and decreased IL-12 in patients with thyroid-associated ophthalmopathy.
Zhang P; Zhang X; Xu F; Xu W; Zhu H
Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):1091-1100. PubMed ID: 36370169
[TBL] [Abstract][Full Text] [Related]
22. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy: correlation with clinical features.
Gopinath B; Musselman R; Adams CL; Tani J; Beard N; Wall JR
Thyroid; 2006 Oct; 16(10):967-74. PubMed ID: 17042681
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
[TBL] [Abstract][Full Text] [Related]
24. [Progression of the pathogenesis of thyroid associated ophthalmopathy].
Wang L; Ma JM
Zhonghua Yan Ke Za Zhi; 2017 Jun; 53(6):474-480. PubMed ID: 28606272
[TBL] [Abstract][Full Text] [Related]
25. IL-17A Exacerbates Fibrosis by Promoting the Proinflammatory and Profibrotic Function of Orbital Fibroblasts in TAO.
Fang S; Huang Y; Wang S; Zhang Y; Luo X; Liu L; Zhong S; Liu X; Li D; Liang R; Miranda P; Gu P; Zhou H; Fan X; Li B
J Clin Endocrinol Metab; 2016 Aug; 101(8):2955-65. PubMed ID: 27224264
[TBL] [Abstract][Full Text] [Related]
26. Antibody-dependent cell-mediated cytotoxicity against orbital target cells in thyroid-associated ophthalmopathy and related disorders; close relationship between serum cytotoxic antibodies and parameters of eye muscle dysfunction.
Barsouk A; Peele KA; Kiljanski J; Stolarski C; Nebes V; Kennerdell JS; Volpe R; Wall JR
J Endocrinol Invest; 1996 Jun; 19(6):334-41. PubMed ID: 8844451
[TBL] [Abstract][Full Text] [Related]
27. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
28. [Emphasizing the fundamental and clinical research on thyroid-associated ophthalmopathy].
Wu ZY; Song GX
Zhonghua Yan Ke Za Zhi; 2005 Sep; 41(9):769-71. PubMed ID: 16191339
[TBL] [Abstract][Full Text] [Related]
29. Integrative transcriptomics and proteomic analysis of extraocular muscles from patients with thyroid-associated ophthalmopathy.
Wu L; Zhang S; Li X; Yao J; Ling L; Huang X; Hu C; Zhang Y; Sun X; Qin B; Liu G; Zhao C
Exp Eye Res; 2020 Apr; 193():107962. PubMed ID: 32057773
[TBL] [Abstract][Full Text] [Related]
30. Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy.
Smith TJ
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101383. PubMed ID: 32088116
[TBL] [Abstract][Full Text] [Related]
31.
Sun B; Zhang Z; Dong C; Zhang Y; Yan C; Li S;
Eye (Lond); 2017 May; 31(5):668-676. PubMed ID: 28387769
[TBL] [Abstract][Full Text] [Related]
32. Development and application of animal models to study thyroid-associated ophthalmopathy.
Shen F; Liu J; Fang L; Fang Y; Zhou H
Exp Eye Res; 2023 May; 230():109436. PubMed ID: 36914000
[TBL] [Abstract][Full Text] [Related]
33. Integrative metabolic analysis of orbital adipose/connective tissue in patients with thyroid-associated ophthalmopathy.
Huang J; Chen M; Liang Y; Hu Y; Xia W; Zhang Y; Zhao C; Wu L
Front Endocrinol (Lausanne); 2022; 13():1001349. PubMed ID: 36465658
[TBL] [Abstract][Full Text] [Related]
34. Th1, Th2, and Th17 Cytokine Involvement in Thyroid Associated Ophthalmopathy.
Shen J; Li Z; Li W; Ge Y; Xie M; Lv M; Fan Y; Chen Z; Zhao D; Han Y
Dis Markers; 2015; 2015():609593. PubMed ID: 26089587
[TBL] [Abstract][Full Text] [Related]
35. Increased generation of fibrocytes in thyroid-associated ophthalmopathy.
Douglas RS; Afifiyan NF; Hwang CJ; Chong K; Haider U; Richards P; Gianoukakis AG; Smith TJ
J Clin Endocrinol Metab; 2010 Jan; 95(1):430-8. PubMed ID: 19897675
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease.
Stein JD; Childers D; Gupta S; Talwar N; Nan B; Lee BJ; Smith TJ; Douglas R
JAMA Ophthalmol; 2015 Mar; 133(3):290-6. PubMed ID: 25502604
[TBL] [Abstract][Full Text] [Related]
37. Insights Into Local Orbital Immunity: Evidence for the Involvement of the Th17 Cell Pathway in Thyroid-Associated Ophthalmopathy.
Fang S; Huang Y; Wang N; Zhang S; Zhong S; Li Y; Sun J; Liu X; Wang Y; Gu P; Li B; Zhou H; Fan X
J Clin Endocrinol Metab; 2019 May; 104(5):1697-1711. PubMed ID: 30517642
[TBL] [Abstract][Full Text] [Related]
38. Hyaluronic acid induces COX-2 expression via CD44 in orbital fibroblasts from patients with thyroid-associated ophthalmopathy.
Lim HS; Back KO; Kim HJ; Choi YH; Park YM; Kook KH
Invest Ophthalmol Vis Sci; 2014 Oct; 55(11):7441-50. PubMed ID: 25342622
[TBL] [Abstract][Full Text] [Related]
39. Serological reactivity of recombinant 1D autoantigen and its expression in human thyroid and eye muscle tissue: a possible autoantigenic link in Graves' patients.
Kromminga A; Hagel C; Arndt R; Schuppert F
J Clin Endocrinol Metab; 1998 Aug; 83(8):2817-23. PubMed ID: 9709953
[TBL] [Abstract][Full Text] [Related]
40. Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients.
Sieminska L; Niedziolka D; Pillich A; Kos-Kudla B; Marek B; Nowak M; Borgiel-Marek H
J Endocrinol Invest; 2008 Sep; 31(9):745-9. PubMed ID: 18997483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
